Patents Examined by Ram R. Shukla
-
Patent number: 11590171Abstract: Provided herein are methods and compositions for editing the genome of a human T cell. In some embodiments, a heterologous T cell receptor (TCR)-? chain and a heterologous TCR-? chain are inserted into exon 1 of a TCR subunit constant gene in the genome of the T cell.Type: GrantFiled: April 20, 2022Date of Patent: February 28, 2023Assignee: The Regents of the University of CaliforniaInventors: Theodore Lee Roth, Eric Shifrut, Alexander Marson, Cristina Puig Saus, Antoni Ribas
-
Patent number: 11578309Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and/or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and/or a different survival factor.Type: GrantFiled: December 31, 2021Date of Patent: February 14, 2023Assignee: CRISPR THERAPEUTICS AGInventors: Alireza Rezania, Valentin Sluch
-
Patent number: 11525120Abstract: Provided herein are methods of producing ? cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.Type: GrantFiled: September 10, 2021Date of Patent: December 13, 2022Assignee: Vertex Pharmaceuticals IncorporatedInventors: Felicia J. Pagliuca, George Harb, Lillian Ye
-
Patent number: 11505783Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells and the products related to or resulting from such methods. In particular, the present invention provides an improved method for the formation of pancreatic hormone expressing cells and pancreatic hormone secreting cells. In addition, the present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer and the products related to or resulting from such methods. The present invention also provides methods to promote glucose-stimulated insulin secretion in insulin-producing cells derived from pluripotent stem cells.Type: GrantFiled: September 27, 2019Date of Patent: November 22, 2022Assignee: Janssen Biotech, Inc.Inventor: Alireza Rezania
-
Patent number: 11499166Abstract: The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.Type: GrantFiled: April 26, 2021Date of Patent: November 15, 2022Assignee: 4D Molecular Therapeutics Inc.Inventors: Melissa Kotterman, Peter Francis, Melissa Calton, Johnny Gonzales, Roxanne Croze, Christopher Schmitt
-
Patent number: 11477970Abstract: The present disclosure provides transgenic nematode systems for assessing function of heterologous genes, their variants and drug discovery. The transgenic nematodes contain a heterologous gene that is inserted via homologous recombination at the native locus replacing and removing the nematode ortholog, wherein expression of the heterologous gene rescues function of the removed nematode ortholog and a transgenic control animal is provided. The heterologous gene may be further modified to provide a variant, such as a human clinical variant, whereby a transgenic test animal is provided. Those transgenic test animals are used in methods to assess function of the heterologous variant and drug screens to find therapeutic candidates reversing deviant activity back to wildtype.Type: GrantFiled: February 21, 2019Date of Patent: October 25, 2022Assignee: NemaMetrix Inc.Inventors: Christopher E. Hopkins, Trisha J. Brock, Kathryn McCormick, Gongping He
-
Patent number: 11433103Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.Type: GrantFiled: July 23, 2021Date of Patent: September 6, 2022Assignee: CRISPR THERAPEUTICS AGInventors: Alireza Rezania, Rebeca Ramos-Zayas
-
Patent number: 11311579Abstract: The present invention provides a method for producing a cell culture for promoting angiogenesis or axon outgrowth, particularly for the treatment of a cerebrovascular disease, an ischemic cardiac disease or traumatic brain injury and spinal cord injury, which comprises culturing a cell population containing microglia and/or monocytes under conditions of low oxygen concentration and/or low sugar concentration to produce the culture, a cell preparation obtained by the method, and a method for treating a cerebrovascular disease, an ischemic cardiac disease or traumatic cerebrospinal neuropathy by using the cell preparation.Type: GrantFiled: August 30, 2017Date of Patent: April 26, 2022Assignee: NIIGATA UNIVERSITYInventors: Takayoshi Shimohata, Masato Kanazawa
-
Patent number: 10905742Abstract: The present invention provides an agent for protecting the liver and/or promoting liver regeneration, which contains a heparin-binding EGF-like growth factor-like growth factor (HB-EGF) or a partial peptide thereof, or a nucleic acid that encodes same, and an agent for the prophylaxis or treatment of liver diseases. The present invention further provides a method for producing a cell for liver protection and/or promoting liver regeneration, and for the prophylaxis/treatment of a liver disease, which includes introducing a nucleic acid that encodes HB-EGF or a partial peptide thereof into a cell collected from an animal.Type: GrantFiled: September 28, 2006Date of Patent: February 2, 2021Assignee: KAGOSHIMA UNIVERSITYInventors: Ken-ichiro Kosai, Cin Khai Ngin, Tomoyuki Takahashi
-
Patent number: 10330690Abstract: The application describes methods for determining the concentration and/or particle number of a lipoprotein(a) subform in a biological sample using capillary isotachophoresis laser induced fluorescence (CE-ITP-LIF) and compositional analysis of lipoprotein(a) particles. The ability to measure the concentration and/or particle number of a lipoprotein(a) subform in a biological sample provides a useful diagnostic tool for assessing cardiovascular risk in a subject.Type: GrantFiled: October 27, 2015Date of Patent: June 25, 2019Assignee: HELENA LABORATORIES CORPORATIONInventors: Philip Guadagno, Erin Grace (Summers) Bellin
-
Patent number: 10288627Abstract: The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits.Type: GrantFiled: September 13, 2011Date of Patent: May 14, 2019Assignee: D-Gen LimitedInventors: Graham Stuart Jackson, John Collinge, Julie Ann Edgeworth
-
Patent number: 10161928Abstract: A panel for monitoring levels of biomarkers, including an assay having at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test. A method of monitoring an individual's health, by collecting a sample from the individual, applying the sample to an assay panel, performing at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test in the panel, and determining levels of biomarkers related to inflammation, oxidative stress, and antioxidant activity and therefore providing information regarding the individual's relative health and/or risk of developing one or more diseases.Type: GrantFiled: July 21, 2011Date of Patent: December 25, 2018Assignee: Wellmetris, LLCInventors: Andrew A. Dahl, Denis M. Callewaert
-
Patent number: 10145853Abstract: The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis. Specifically, 35 kDa protein fragment consisting of amino acid sequence expressed by Sequence No. 2 and its partial peptide consisting of amino acid sequence expressed by Sequence No. 3 (including its glycated form) of inter-alpha-trypsin inhibitor heavy chain H4 precursor consisting of amino acid sequence expressed by Sequence No.Type: GrantFiled: April 6, 2015Date of Patent: December 4, 2018Assignee: MCBI, Inc.Inventors: Kohji Meno, Hideaki Suzuki
-
Patent number: 10041951Abstract: An imaging probe can include a photoluminescent carbon nanostructure configured to emit a wavelength of light detectable through living tissue, and a targeting moiety including a first binding partner configured to interact with a second binding partner.Type: GrantFiled: January 31, 2013Date of Patent: August 7, 2018Assignee: Massachusetts Institute of TechnologyInventors: Hyunjung Yi, Debadyuti Ghosh, Jifa Qi, Angela M. Belcher, Michael S. Strano, Neelkanth M. Bardhan
-
Patent number: 10001440Abstract: An observation apparatus and an observation method are provided. The observation apparatus includes a light source that emits illumination light used to observe a specimen to which a fluorescent substance that specifically binds to or is expressed in a stimulus target has been supplied, an illumination optical system that radiates the illumination light emitted from the light source 11 onto the specimen, a deflecting device that changes an area of the specimen to be irradiated with the illumination light, a wavelength selecting section that selects the wavelength of illumination light to be radiated onto the specimen, an observation optical system that collects light from the specimen, a detector that detects the light collected by the observation optical system, an image processing section that generates an image from the light detected by the detector, and a control section that controls these components.Type: GrantFiled: March 7, 2014Date of Patent: June 19, 2018Assignee: OLYMPUS CORPORATIONInventor: Susumu Honda
-
Patent number: 9957331Abstract: Herein are reported the cell lines DSM ACC3006, DSM ACC3007, and DSM ACC3008, as well as the antibodies obtained from the cell lines and the use of an antibody obtained from the cell lines in an immunoassay. Also are reported antibodies binding to human or chimpanzee IgG and not binding to canine and marmoset IgG and antibodies specifically binding to an IgG 1 that comprises a kappa light chain constant domain.Type: GrantFiled: October 18, 2010Date of Patent: May 1, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Essig, Stefan Klostermann, Frank Kowalewsky, Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
-
Patent number: 9915664Abstract: The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis.Type: GrantFiled: August 16, 2011Date of Patent: March 13, 2018Assignee: MEDIZINISHCE HOCHSCHULE HANNOVERInventors: Niklas Thomas Baerlecken, Torsten Witte
-
Patent number: 9897615Abstract: Disclosed is the invention to conduct immuno-adsorption of free 25(OH) vitamin D from blood or blood components, notably serum or plasma, after which the absorbed material is measured. A fluoro-alkyl surfactant is used to enhance the solubility of Vitamin D and allow the measurement of free Vitamin D. The invention thus employs a binding protein to absorb the free 25(OH) vitamin D. Thereafter the binding protein comprising the 25-OH vitamin D is subjected to a competitive binding assay with a labeled vitamin D compound, preferably radiolabeled, fluorescent labeled, luminescent labeled, biotin labeled, gold labeled or enzyme labeled. Alternatively the immunocaptured 25-OH vitamin D can be quantitated by mass spectrometry.Type: GrantFiled: April 1, 2011Date of Patent: February 20, 2018Assignee: Future Diagnostics, B.V.Inventors: Michaƫl Franciscus Wilhelmus Cornelis Martens, George Henry Parsons, Franciscus Maria Anna Rosmalen, Leon Maria Jacobus Wilhelmus Swinkels
-
Patent number: 9868940Abstract: Herein is described a novel hybridoma cell line (RMH359) and its use as a cellular bioassay to determine the efficacy of cell conditioned media (CCM) as a supplement used to support cell survival and promote growth in culture. This bioassay is the first to provide a measure of CCM bioactivity in support of hybridoma cells used in the generation and production of monoclonal antibodies.Type: GrantFiled: September 15, 2015Date of Patent: January 16, 2018Assignee: The United States of America, as represented by The Secretary of AgricultureInventors: Robert M. Hnasko, Larry H. Stanker, Jeffery A. McGarvey, Alice V. Lin
-
Patent number: 9863941Abstract: A microchip with flow-through inlet (104) and outlet (106) channels and test channels (108). The test channels (108) are in fluid communication with the inlet (104) and outlet (106) channels, through inlets (114) and outlets (116) respectively. Each test channel (108) has one test site therein for detection of specific molecules or molecular interactions. The inlet (114) in a test channel (108) is elevated from the outlet (116) of the test channel (108) and the outlet (116) is elevated from a fluid level (124) in the outlet channel (106). Back diffusion from outlet channel (106) to the test channels (108) and from the test channels (108) to the inlet channel (104) can thus be inhibited to reduce or eliminate cross-interference between different test sites. The microchip can be useful as a flow-through high density enzyme immunoassay array device with high-throughput.Type: GrantFiled: April 1, 2005Date of Patent: January 9, 2018Assignee: Nanyang Technological UniversityInventor: Changming Li